ProQR Therapeutics NV (PRQR) - Forward P/S Multiple
The implementation of robotic RNA oligonucleotide synthesis systems automates precision molecule screening. The forward P/S ratio demonstrates the impact of liquidity on capitalization, with the value holding around 9.00. ProQR Therapeutics N.V. (PRQR) maintains high authority in ophthalmology, offering hope to patients with rare pathologies, while an inclusive culture and RSU plans help retain leading molecular biologists.
Metric breakdowns and analytics for proqr.com (PRQR)
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio ProQR Therapeutics N.V.|PRQR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio ProQR Therapeutics|PRQR - Company Cumulative Indebtedness|Debts to Book Capitalization PRQR|PRQR - Long-Term Debt Volume|Company Short-Term Debts ProQR Therapeutics N.V.|Quick Liquidity proqr.com
- business earnings and investment ratios data:
PRQR - Net Financial Result|Future Profit ProQR Therapeutics N.V.|PRQR - Company Value to Net Income|Future Price to Earnings ProQR Therapeutics|PRQR - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio PRQR|PRQR - Operating income before deduction of amortization|Net earnings per share for the last 12 months ProQR Therapeutics N.V.|PRQR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months proqr.com|PRQR - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year ProQR Therapeutics N.V.
- sales volume and revenue information:
General company analysis:ProQR Therapeutics NV PRQR
The forward P/S ratio measures an asset's market value relative to expected revenues, providing a real-time assessment of investors' willingness to pay a premium for future growth. By analyzing the expected price-to-sales ratio, one can determine the risk of overvaluation: for ProQR Therapeutics N.V. (PRQR), unique RNA editing patents and alliances with pharma behemoths justify a high premium, offsetting the pressure of current competition on market capitalization.
Analysis of competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|RGEN - Forward P/S Multiple|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CRSP (crisprtx.com)|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Forward P/S Multiple Sarepta Corp (SRPT)|Twist Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke Therapeutics Inc STOK|BLFS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PRME (Prime Medicine)|TSHA (Taysha Gene Therapies Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX: Market Cap to Projected Revenue|RGNX: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio solidbio.com SLDB|OCGN (Ocugen) - Forward Price-to-Revenue Multiple|PACB (Pacific Biosciences of California, Inc.) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple BNTC|Design Corp (DSGN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|FDMT: Future Price to Revenue|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Projected Price to Revenue Silence Therapeutics Corp (SLN)|codexis.com (CDXS) - Price-to-Projected Revenue Ratio|sangamo.com - Forward Price to Sales|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Price-to-Projected Revenue Ratio Precision BioSciences, Inc. (DTIL)|generationbio.com - Market Cap to Projected Revenue|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Forward P/S Multiple Exicure Inc. XCUR|IMNN - Price-to-Projected Revenue Ratio|Future Price to Revenue PHIO|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|TransCode Therapeutics, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|Market Cap to Future Revenue Ratio adnas.com APDN|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|immunoprecise.com (IPA) - Projected Price to Revenue|Price-to-Projected Revenue Ratio Omega OMGA|Forward Price to Sales OMIC|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (syros.com)|TBIO (Telesis Bio) - Forward Price-to-Revenue Multiple|TCON: Price to Expected Revenue Ratio|UBX (Unity Bio) - Forward P/S Multiple
